Epigenomics appoints new US head
This article was originally published in Clinica
German cancer diagnostics specialist Epigenomics has appointed Noel Doheny as CEO of its US subsidiary. Mr Doheny has over 30 years' experience in diagnostics. He was most recently CEO of molecular diagnostics company OpGen and has held other senior management positions at Affymetrix and Qiagen. Mr Doheny will start his new role at Seattle, Washington-based Epigenomics Inc next month and help to build its US sales force as the company prepares to submit its premarket approval application to the FDA for its Epi proColon 2.0 coloeretal cancer test.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.